Insider Brief
- AiM Medical Robotics closed an $8.1M Series A led by IQ Capital and 1540 Ventures to advance its MRI-compatible neurosurgery robot toward first-in-human trials.
- The platform combines real-time intraoperative MRI with robotic guidance to precisely place neurostimulation leads and supports cranial procedures such as biopsy, ablation, and targeted drug delivery.
- The round (initial close June 2025, including $3.75M in converted notes) drew backing from WPI, Sontag Innovation Fund, Cancer Research Horizons, and multiple angel groups, with proceeds for the first-in-human study, partnerships, product development, and regulatory milestones.
PRESS RELEASE — AiM Medical Robotics Inc. (AiM), a pioneer in MRI-compatible surgical robotic systems, announced the successful closing of its $8.1 million Series A financing round. The round was led by IQ Capital (London, UK) and 1540 Ventures (New York, USA), with enthusiastic participation from new and returning strategic investors.
“AiM is advancing neurosurgery with a novel robotic platform that integrates seamlessly into existing workflows and provides surgeons with real-time imaging to achieve safer, more precise, and more consistent outcomes for patients,” said Alex Wilson, Partner at I“AiM is advancing neurosurgery with a novel robotic platform that integrates seamlessly into existing workflows and provides surgeons with real-time imaging to achieve safer, more precise, and more consistent outcomes for patients,” said Alex Wilson, Partner at IQ Capital. “We’re excited to support the company as it moves toward first-in-human trials and clinical adoption.”
AiM’s breakthrough technology enables surgeons to perform precise neurosurgical procedures directly within an MRI — addressing intraoperative shift and eliminating the need to move patients between operating rooms and imaging suites. The Company’s groundbreaking neurosurgery system leverages real-time intraoperative MRI coupled with robotic guidance to ensure precise placement of neurostimulation leads for Parkinson’s disease patients. AiM’s cutting-edge robotic surgery platform also extends to a wide range of cranial procedures including biopsy, tumor ablation, and targeted intracranial delivery of novel therapeutics. This integration offers to make procedures faster, safer, and consistently more accurate while reducing patient risk and healthcare costs.
With an initial close in June 2025, the Series A totaled $8.1 million including $3.75 million in notes converted into equity. The financing round attracted a broad base of world-class investors, with significant investment from institutions including IQ Capital, 1540 Ventures, and Worcester Polytechnic Institute (WPI); brain cancer impact investors such as the Sontag Innovation Fund (subsidiary of the Sontag Foundation) and Cancer Research Horizons (affiliate of Cancer Research UK); and prominent angel investor groups including New York Angels (NYA), Harvard Business School Alumni Angels (HBSAA), SWAN Impact Network, Angel Star Ventures, and Keiretsu Forum. To date, AiM has raised over $11.3 million in investment, further bolstered by significant federal grant support for the underlying technology.
“This investment marks the beginning of the next chapter for AiM as we prepare to bring our transformative technology to patients,” said Dr. Gregory Fischer, co-founder and CEO of AiM Medical Robotics, Inc. “With first patient enrollment on the horizon, we are eager to demonstrate the profound clinical and commercial impact of AiM’s platform – not only in Parkinson’s disease but across a broad spectrum of cranial procedures including tumor biopsy, cancer and epilepsy ablation, and targeted intracranial drug delivery that will support the burgeoning field of stem cell and gene therapy.”
The Series A proceeds will fund AiM’s first-in-human clinical study, expand strategic partnerships, and accelerate product development and regulatory milestones.
